Technical Field
The present disclosure relates generally to medical/surgical ablation procedures. More particularly, the present disclosure relates to devices and microwave radiation delivery procedures utilizing microwave antenna assemblies and methods of controlling the delivery of microwave radiation to tissue.
Background of Related Art
In the treatment of diseases such as cancer, certain types of cancer cells have been found to denature at elevated temperatures (which are slightly lower than temperatures normally injurious to healthy cells). These types of treatments, known generally as hyperthermia therapy, typically utilize electromagnetic radiation to heat diseased cells to temperatures above 41° C. while maintaining adjacent healthy cells at lower temperatures where irreversible cell destruction will not occur. Other procedures utilizing electromagnetic radiation to heat tissue also include ablation and coagulation of the tissue. Such microwave ablation procedures, e.g., such as those performed for menorrhagia, are typically done to ablate and coagulate the targeted tissue to denature or kill it Additionally, microwave therapy may be used in the treatment of tissue and organs such as the prostate, heart, and liver.
One advantage of microwave therapy is that microwave energy is able to non-invasively penetrate the skin to reach underlying tissue. Unlike low frequency RF therapy, which heats tissue with current, microwave therapy heats tissue within the electromagnetic field generated by a microwave antenna. The electromagnetic field generated by the microwave antenna generates a predictably large and/or uniform ablation region.
A second advantage of microwave therapy is that energy is rapidly delivered to the target tissue resulting in the reduction of surgical procedure time. During a typical surgical procedure microwave energy rapidly heats tissue to a target temperature and maintains the tissue above the target temperature for a required period of time.
Rapid delivery of heat to tissue may also result in the unwanted heating of healthy tissue or overheating of the target tissue. Unwanted heating of healthy tissue may be the result of creating an electromagnetic field larger than is required or excessive energy delivery. Overheating of tissue may result from excessive energy delivery or inconsistent heating of the target tissue.
Thus, the non-invasive use of microwave energy requires a great deal of control. This is partly why a more direct and precise method of delivering microwave radiation has been sought. The present disclosure provides a system for supplying microwave and various methods of delivering microwave radiation to tissue.
The present disclosure relates generally medical/surgical ablation procedures. More particularly, the present disclosure relates to monitoring characteristics of microwave radiation delivery procedures utilizing microwave antenna assemblies configured for direct insertion into tissue and methods of controlling the delivery of microwave radiation to tissue.
A system for supplying microwave energy for microwave therapy of the present disclosure comprises an electrosurgical generator including a microwave energy source and a controller for controlling the operation of an electrosurgical generator. The electrosurgical generator includes an output for coupling to a surgical instrument which includes a microwave antenna for delivering microwave energy. The controller being operable for causing the electrosurgical generator to apply two or more pulses of microwave energy to the tissue.
The controller may be configured to measure an electrical characteristic of at least one of the at least two pulses of microwave energy. Controller may be responsive to the measured electrical characteristic of at least one of the at least two pulses of microwave energy for determining at least one pulse parameter of a subsequent microwave energy pulse. The pulse parameter may be selected from a group consisting of power, frequency, pulse duration, pulse shape, pulse duty cycle and time between pulses. The electrical characteristic may be related to reflective power. The controller may vary the power of each of the pulses of microwave energy. Controller may also be responsive to a control input from an operator for modifying any one of the at least one pulse parameters.
A method for applying microwave energy to target tissues includes the steps of positioning the microwave energy delivery device into or adjacent a portion of the target tissue and delivering at least two pulses of microwave energy to the target tissue wherein a substantial portion of the microwave energy is reduced between the at least two pulses of microwave energy. The delivering step may include the steps of heating a portion of the target tissue to a target temperature and maintaining the portion of the target tissue at or above the target temperature.
In another embodiment the step of delivering the at least two pulses of microwave energy may include the step of selecting and varying at least one parameter thereof. The step of selecting and varying the at least one parameter may further include the step of selecting the at least one parameter from a group consisting of power, frequency, pulse duration, pulse shape, phase, pulse duty cycle and time between pulses.
In yet another embodiment the step of delivering the at least two pulses of microwave energy may include the step of varying at least one of the at least two pulses of microwave energy in accordance with at least one characteristic of an electrical transient of one of the at least two pulses of microwave energy.
In yet another embodiment the step of delivering the at least two pulses of microwave energy may include the step of selecting parameters of the at least two pulses of microwave energy such that a rise in target tissue temperature is about zero.
In yet another embodiment the step of delivering the at least two pulses of microwave energy may include the steps of measuring at least one characteristic of the target tissue in response to one of the at least two pulses of microwave energy and in accordance with the at least one characteristic of the target tissue, determining whether to change the microwave energy parameters. The step of measuring the at least one characteristic of tissue may further include the step of selecting the at least one characteristic of the tissue from a group consisting of a characteristic related to reflective power, a characteristic related to tissue temperature, and a characteristic related to tissue impedance. The method may further include the step of determining a response of the target tissue to one of the at least two pulses of microwave energy.
In yet another embodiment the step of delivering the at least two pulses of microwave energy may include the steps of measuring at least one characteristic of one of the at least two pulses of microwave energy and in accordance with the at least one measured characteristic, determining whether to change at least one microwave energy parameter. The step of measuring the at least one characteristic of one of the at least two pulses of microwave energy may include the step of selecting at least one characteristic related to reflective power. The method may further include the steps of measuring at least one characteristic of one of the at least two pulses of microwave energy and in accordance with the at least one measured characteristic, at least one of determining whether to terminate the application of microwave energy to tissue, and using the at least one measured characteristic to determine a set of microwave energy parameters for a subsequent pulse of microwave energy. The at least one microwave energy parameter may be selected from a group consisting of power, frequency, pulse duration, pulse shape, phase, pulse duty cycle and time between pulses.
In yet another embodiment the method of positioning the microwave energy delivery device into or adjacent a portion of the target tissue and delivering at least two pulses of microwave energy may include the steps of measuring at least one characteristic of the target tissue in response to one of the at least two pulses of microwave energy; and in accordance with the at least one characteristic of the target tissue, at least one of determining whether to terminate the application of microwave energy, and using the at least one characteristic of the target tissue to determine a set of microwave energy parameters for applying a subsequent pulse of microwave energy. The set of microwave energy parameters for the application of a subsequent pulse of microwave energy may includes a magnitude of a microwave power, a pulse shape, pulse duration and any combination thereof.
The delivery of microwave energy may be terminated upon a determination that a predetermined condition is satisfied. The predetermined condition is selected from a group consisting of treatment duration, a condition related to temperature and a condition related to reflective power.
In yet another embodiment of the present disclosure a method for applying microwave energy to a target tissue, includes the steps of positioning a microwave energy delivery device into or adjacent a portion of the target tissue, delivering at least two pulses of microwave energy to the target tissue wherein a substantial portion of the microwave energy is reduced between the at least two pulses of microwave energy, measuring at least one of the temperature of a transmission line and a temperature of the microwave energy delivery device, and varying at least one of the at least two pulses of microwave energy in response to the at least one of the measured temperatures.
Embodiments of the presently disclosed microwave antenna assembly will now be described in detail with reference to the drawing figures wherein like reference numerals identify similar or identical elements. As used herein and as is traditional, the term “distal” refers to the portion of the device or instrument that is furthest from the user and the term “proximal” refers to the portion of the device or instrument that is closest to the user. In addition, terms such as “above”, “below”, “forward”, “rearward”, etc. refer to the orientation of the figures or the direction of components and are simply used for convenience of description.
Two factors in the treatment of diseased tissue with microwave therapy include the proper positioning and placement of a microwave antenna relative to the target tissue, and the delivery of microwave energy.
The step of positioning and placement of a microwave antenna, relative to target tissue, is dependant upon the location of the target tissue. One method of accessing target tissue involves the insertion of the microwave antenna into an existing body lumen, such as, for example, accessing the inner chambers of the heart through the vascular system, accessing the prostate by inserting a microwave antenna through the urethra or accessing the lungs and esophagus by inserting a microwave antenna through the mouth cavity. Various methods and devices are provided for in U.S. Pat. No. 5,916,241, entitled “Device and Method for Asymmetrical Thermal Therapy with Helical Dipole Microwave Antenna”, to Rudie et al., describing accessing the prostate through the urethra, and U.S. Pat. No. 7,070,595, entitled “Radio-Frequency Based Catheter System and Method for Ablating Biological Tissue”, to Ormsby et al., describing accessing cardiac tissue through the vascular system.
Another method of accessing target tissue involves direct insertion of a device into tissue. A microwave antenna may be formed or inserted through a delivery device such as, for example, an introducer or catheter, as described in U.S. Pat. No. 6,355,033, entitled “Track Ablation Devices and Methods”, to Moorman et al. The microwave antenna may also be sufficiently strong to allow direct insertion into tissue as described in U.S. Pat. No. 6,878,147, entitled “High Strength Microwave Antenna Assemblies”, to Prakash et al. Yet another microwave device may be inserted into tissue in a first condition followed by deployment of the distal penetrating portion thereof to a second condition thereby forming a microwave antenna at the distal end of the assembly as described in U.S. application Ser. No. 10/272,314, entitled “Microwave Antenna Having a Curved Configuration”, to Prakash et al.
The delivery of microwave energy is also dependant upon the location of the target tissue. Ormsby et al. '595 describes delivery of RF energy in the vascular system that generates and delivers a continuous train of radio frequency energy pulses at an output frequency for transmission in a transmission line to a shapeable RF antenna. The output frequency is adjusted based on the sensed reflective signal in order to substantially match the transmission line impedance with the shapeable RF antenna and the biological tissue load impedance. Rudie et al. '241 describes delivery of a continuous train of microwave energy in the urological system. In both Ormsby et al. '595 and Rudie et al. '241 the output frequency is adjusted to reduce the risk of overheating by the electrical transmission and to prevent damage to the lumen in which the transmission line is contained.
The present disclosure provides a system for supplying microwave energy and various methods of delivering microwave radiation to tissue with a microwave device. A microwave device of the system for supplying microwave energy may be inserted directly into tissue, inserted through a lumen, such as, for example, a vein, needle or catheter, placed into the body during surgery by a clinician or positioned in the body by other suitable methods or means known in the art. While the method described hereinbelow is targeted toward microwave ablation and the complete destruction of target tissue, the methods may be used with other microwave therapies in which the target tissue is partially damaged, e.g. in order to prevent the electrical conduction in heart tissue.
Referring now to
Device 30 is illustrated as a microwave antenna sufficiently strong to allow direct insertion or penetration into tissue, although microwave antenna may be any device suitably capable of delivering microwave energy or the like.
System 10 may include one or more sensors to measure various parameters associated with the delivery of microwave energy. For example, device 30 and/or transmission line 34 may include one or more suitable temperature measuring sensor 35, 36. As seen in
During operation of system 10, as seen in
The desired therapeutic result may also impact the shape of the individual waveforms. For example, during tissue ablation tissue temperature may rise to about 60° C. to 70° C. and the clinician may maintain the tissue at a temperature for a target amount of time. Other treatments may require raising tissue to a temperature less than 60° C. or may not require maintaining the tissue at a target temperature.
With continued reference to
During the initial delivery of microwave energy to patient tissue “PT”, between 0 and 70 seconds, the antenna 32 is matched to the tissue properties and reflective power “RP” is at a minimum at a level slightly more than zero. Between 90 and 100 seconds the properties of patient tissue “PT” begin to change and reflective power “RP” begins to increase. This increase in reflective power “RP” indicates that the antenna 32 is less “tuned”, or matched to the properties of tissue “PT”, and less power is delivered to tissue “PT”. At this point, electrosurgical generator 20 continues to maintain constant forward power “FP” and the antenna 32 become less efficient and reflective power continues to increase.
Reflective power may be reduced by adjusting the frequency of the delivered microwave energy to match the impedance of the damaged tissue. The present disclosure provides for a system and method of controlling the delivery of microwave energy in order to prevent and/or minimize a change in tissue impedance, thus preventing further increases in reflective power.
With reference to
Controller 22 may also be responsive to an individual measurement related to microwave energy delivery, such as, for example, an instantaneous or time weighted measurement of temperature, power or impedance.
With reference to
Controller 22 is operable to remove, reduce or turn off the delivery of energy 110-110n to patient tissue “PT” between energy pulses 100-100n. With reference to
The energy pulse generated by the controller, irrespective of the method of generation, is characterized by delivery of energy to tissue for an amount of time followed by a second amount of time wherein the energy delivered to tissue is substantially reduced. Preferably, the energy delivered to tissue during the second amount of time is reduced to a level that is metabolically insignificant, or equal to the basal metabolism level of about 1 W/kg of tissue.
The controller 22 may include means for switching (not explicitly shown) the delivery of energy to secondary load 26. The means for switching may be a separate device included in the electrosurgical generator 20 or it may be an external device controlled by the electrosurgical generator 20. Secondary load may be a resistive load, for absorbing and/or dissipating the energy, an additional electrosurgical device, such as, for example, a microwave antenna, or any combination thereof.
With continued reference to
Providing microwave energy as a series of pulses, separated by delays, wherein the energy is removed or substantially reduced, improves delivery and dispersion of heat within the target tissue. Removing power provides a relaxation period for the tissue “PT” and enables the tissue “PT” to re-hydrate and recover. Microwave energy is then reapplied to tissue “PT” after the delay or relaxation period and the process may be repeated as needed and/or desired. This periodic redistribution of heat through the tissue “PT” during the relaxation period, followed by the re-delivery and/or re-transmission of microwave energy, improves the ablation size and results in a more predictable ablation area.
Measurements may be continuously or periodically performed during energy delivery, the relaxation period or any combination thereof.
During the delivery of microwave energy, antenna mismatch or reflected power may produce standing waves in the transmission cable 34 and/or device 30 resulting in an increase in the voltage standing wave ratio (hereinafter “VSWR”). Standing waves produce hot spots in the transmission cable 34 at various locations along a length thereof, the hot spots are typically spaced every ½ wavelength along the cable. The location and/or the temperature of the hot spots correspond to a specific characteristic of the standing wave or to the value of the VSWR. Continuous delivery of microwave energy may result in these hot spots exceeding a maximum expectable temperature and may result in patient or clinician injury or damage of equipment.
Providing a series of microwave energy pulses separated by delays, as disclosed herein, may result in even distribution of heat along the transmission path. For example, the delay between consecutive pulses may allow the thermal energy to conduct away from each hot spot resulting in a more even distribution of temperature. In addition, pulsing of microwave energy may change at least one characteristic of the standing wave. For example, the standing wave may change phase or relaxation of patient tissue may change the VSWR. This may result in repositioning or shifting the hot spots between a pulse of microwave energy and a subsequent pulse. Shifting of the location of the hot spots between pulses may result in a more even distribution of heating and/or temperature along the transmission cable 34.
Microwave energy therapy parameters are used to determine the number of microwave energy pulses, the duration and power of each individual energy pulse, the delay between energy pulses and the total duration of the procedure. Individual pulse parameters include the parameters associated with each individual pulse, such as, for example, the duration of the pulse, the frequency of the pulse, the power setting of the pulse and the delay after each individual pulse. With reference to
Controller 22 may be responsive to the measured electrical characteristics of one or more microwave energy pulses. The measured electrical characteristic may be related to reflective power, such as, for example, reflective power magnitude, reflective power phase, reflection loss, reflection coefficient, voltage standing wave ratio (VSWR), return loss, or mismatch loss VSWR. The measured electrical characteristic may be a sensed parameter such as, for example, temperature of the transmission line 34 measured by sensor 35 or the temperature of the device 30 measured by device sensor 36. In operation, controller 22 may adjust one or more parameters of the current energy pulse or of a subsequent microwave energy pulse.
In the operation of one embodiment of the present disclosure, a clinician may view the various electrical characteristics related to reflective power, via the user interface 40 and display 44. The clinician may make adjustments to the microwave energy therapy parameters or pulse parameters based on the various electrical characteristics. The clinician may adjust one or more parameters of the current pulse or of a subsequent pulse or may adjust one or more microwave energy therapy parameters.
A first method of applying microwave therapy to tissue includes the steps of applying a first pulse of microwave energy to tissue, removing a substantial portion of the microwave energy from the tissue and applying at least one subsequent microwave energy pulse to tissue. Removing a substantial portion of the microwave energy may include: reducing the energy to a level that allows the tissue relaxes, reducing the energy to a level that maintains tissue temperature, reducing energy to a level that is metabolically insignificant, or reducing the delivered energy to zero.
As discussed hereinabove and with reference to
After the termination of the initial energy pulse 200, the temperature “T” may continue to rise for a period to time “T2” due to the heat dispersing within the target tissue. The duration of a first off period 210 having a period of time “T3” that may be equal to a predetermined amount of time. Controller 22 may vary the duration of the first off period 210 in response to a characteristic of tissue, a characteristic of a previous microwave energy pulse and/or a characteristic of an electrical transient. In
The individual pulse parameters of the first subsequent energy pulse 200a may be varied according to a characteristic of tissue, a characteristic of the microwave energy pulse or a characteristic of an electrical transient, such as, for example, the duration of the first off period 210. A long “off” period may indicate that the target tissue contains excessive heat energy and the individual pulse parameter may be adjusted to deliver less energy. Alternatively, a short “off” period may indicate that the target tissue quickly disperses the heat energy in the target tissue and the energy of the first subsequent energy pulse should remain the same or may be increased.
Control of the first subsequent energy pulse 200a may be similar to the control of the initial energy pulse 200 or control may be responsive to a different measured parameter or different characteristic of an electrical transient. As the temperature “T” of tissue “PT” increases, steam begins to form at the molecular level and/or the tissue begins to transform. Steam generation and phase transformation effect thermal delivery and dispersion within the target volume and reflective power “RP” will begin to increase. At this point, parameters of the subsequent energy pulses 200c-200i are selected as to not appreciably heat the tissue “PT”.
With continued reference to
A further embodiment of the present method includes the step of measuring at least one characteristic of the microwave energy pulse and determining whether to change the microwave energy parameters. The characteristic may be related to reflective power “RP”, such as, for example, the instantaneous measurement or the rate of change of reflective power “ΔRP”. Energy pulse parameters are selected as to control or maintain selected characteristics.
Reflective power “RP” and the rate of change of reflective power “ΔRP” can be used as an indicator of the condition of tissue. Formation of steam, while conducive to thermal delivery of heat, removes moisture from tissue and changes the impedance of the tissue. A change of tissue impedance creates an imbalance between the antenna and the tissue “PT” which causes an increase in reflective power “RP”. In selecting parameters to maintain or reduce reflective power “RP”, the system 10, while creating some steam, does not damage tissue “PT” resulting in more predictable and/or larger ablation sizes.
According to a further method of the present disclosure, at least one characteristic of the tissue “PT” is measured in response to the applied first pulse. The controller 22, in accordance with the measured characteristic may terminate the delivery of microwave energy to tissue. The controller 22 may also use the measured characteristic to determine a set of microwave energy parameters for a subsequent microwave energy pulse. The steps are then repeated for the subsequent pulses.
In a further embodiment of the present method, the set of microwave energy parameters for the subsequent microwave energy pulse may include at least one of a magnitude of a starting microwave power, pulse shape, pulse duration and any combination thereof.
In a further method of the present disclosure, the delivery of electrosurgical energy, and/or the “off” period, may be adjusted for temperature management of portions of the electrosurgical system or temperature management of patient tissue “PT”. With reference to
The system for supplying microwave energy for microwave therapy and the methods of use discussed above are not limited to microwave antennas used for hyperthermic, ablation, and coagulation treatments but may include any number of further microwave antenna applications. While several embodiments of the disclosure have been shown in the drawings and/or discussed herein, it is not intended that the disclosure be limited thereto, as it is intended that the disclosure be as broad in scope as the art will allow and that the specification be read likewise. Modification of the above-described system and methods for using the same, and variations of aspects of the disclosure that are obvious to those of skill in the art are intended to be within the scope of the claims. Therefore, the above description should not be construed as limiting, but merely as exemplifications of particular embodiments.
This application is a continuation application of U.S. patent application Ser. No. 11/820,679, filed Jun. 20, 2007, the entire contents of which is incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
4140130 | Storm, III | Feb 1979 | A |
4311154 | Sterzer et al. | Jan 1982 | A |
4409993 | Furihata | Oct 1983 | A |
4534347 | Taylor | Aug 1985 | A |
4557272 | Carr | Dec 1985 | A |
4583869 | Chive et al. | Apr 1986 | A |
4612940 | Kasevich et al. | Sep 1986 | A |
4621642 | Chen | Nov 1986 | A |
4658836 | Turner | Apr 1987 | A |
4700716 | Kasevich et al. | Oct 1987 | A |
4776086 | Kasevich et al. | Oct 1988 | A |
4800899 | Elliott | Jan 1989 | A |
4823812 | Eshel et al. | Apr 1989 | A |
4841988 | Fetter et al. | Jun 1989 | A |
4945912 | Langberg | Aug 1990 | A |
5097845 | Fetter et al. | Mar 1992 | A |
5122137 | Lennox | Jun 1992 | A |
5190054 | Fetter et al. | Mar 1993 | A |
5221269 | Miller et al. | Jun 1993 | A |
5234004 | Hascoet et al. | Aug 1993 | A |
5246438 | Langberg | Sep 1993 | A |
5249585 | Turner et al. | Oct 1993 | A |
5275597 | Higgins | Jan 1994 | A |
5281217 | Edwards et al. | Jan 1994 | A |
5301687 | Wong et al. | Apr 1994 | A |
5314466 | Stern et al. | May 1994 | A |
5342355 | Long | Aug 1994 | A |
5344441 | Gronauer | Sep 1994 | A |
5366490 | Edwards et al. | Nov 1994 | A |
5370644 | Langberg | Dec 1994 | A |
5383922 | Zipes et al. | Jan 1995 | A |
5405346 | Grundy et al. | Apr 1995 | A |
5413588 | Rudie et al. | May 1995 | A |
5458597 | Edwards et al. | Oct 1995 | A |
5464445 | Rudie et al. | Nov 1995 | A |
5480417 | Hascoet et al. | Jan 1996 | A |
5500012 | Brucker et al. | Mar 1996 | A |
5507743 | Edwards et al. | Apr 1996 | A |
5509929 | Hascoet et al. | Apr 1996 | A |
5520684 | Imran | May 1996 | A |
5536267 | Edwards et al. | Jul 1996 | A |
5545137 | Rudie et al. | Aug 1996 | A |
5556377 | Rosen et al. | Sep 1996 | A |
5599294 | Edwards et al. | Feb 1997 | A |
5599295 | Rosen et al. | Feb 1997 | A |
5628770 | Thome et al. | May 1997 | A |
5628771 | Mizukawa | May 1997 | A |
5683382 | Lenihan et al. | Nov 1997 | A |
5720718 | Rosen et al. | Feb 1998 | A |
5741249 | Moss et al. | Apr 1998 | A |
5755754 | Rudie et al. | May 1998 | A |
5776176 | Rudie | Jul 1998 | A |
5800486 | Thome et al. | Sep 1998 | A |
5810803 | Moss et al. | Sep 1998 | A |
5810804 | Gough et al. | Sep 1998 | A |
5829519 | Uthe | Nov 1998 | A |
5843144 | Rudie et al. | Dec 1998 | A |
5871523 | Fleischman et al. | Feb 1999 | A |
5897554 | Chia et al. | Apr 1999 | A |
5902251 | vanHooydonk | May 1999 | A |
5904691 | Barnett et al. | May 1999 | A |
5904709 | Arndt et al. | May 1999 | A |
5916240 | Rudie et al. | Jun 1999 | A |
5916241 | Rudie et al. | Jun 1999 | A |
5931807 | McClure et al. | Aug 1999 | A |
5938692 | Rudie | Aug 1999 | A |
5951547 | Gough et al. | Sep 1999 | A |
5957969 | Warner et al. | Sep 1999 | A |
5964755 | Edwards | Oct 1999 | A |
5974343 | Brevard et al. | Oct 1999 | A |
5980563 | Tu et al. | Nov 1999 | A |
5997532 | McLaughlin et al. | Dec 1999 | A |
6016811 | Knopp et al. | Jan 2000 | A |
6026331 | Feldberg et al. | Feb 2000 | A |
6029051 | Osterberg et al. | Feb 2000 | A |
6032078 | Rudie | Feb 2000 | A |
6047216 | Carl et al. | Apr 2000 | A |
6056744 | Edwards | May 2000 | A |
6059780 | Gough et al. | May 2000 | A |
6063078 | Wittkampf | May 2000 | A |
6073051 | Sharkey et al. | Jun 2000 | A |
6080150 | Gough | Jun 2000 | A |
6097985 | Kasevich et al. | Aug 2000 | A |
6106518 | Wittenberger et al. | Aug 2000 | A |
6122551 | Rudie et al. | Sep 2000 | A |
6134476 | Arndt et al. | Oct 2000 | A |
6146379 | Fleischman et al. | Nov 2000 | A |
6176856 | Jandak et al. | Jan 2001 | B1 |
6181970 | Kasevich | Jan 2001 | B1 |
6217528 | Koblish et al. | Apr 2001 | B1 |
6223086 | Carl et al. | Apr 2001 | B1 |
6226553 | Carl et al. | May 2001 | B1 |
6233490 | Kasevich | May 2001 | B1 |
6235048 | Dobak, III | May 2001 | B1 |
6245064 | Lesh et al. | Jun 2001 | B1 |
6251128 | Knopp et al. | Jun 2001 | B1 |
6275738 | Kasevich et al. | Aug 2001 | B1 |
6277113 | Berube | Aug 2001 | B1 |
6289249 | Arndt et al. | Sep 2001 | B1 |
6290715 | Sharkey et al. | Sep 2001 | B1 |
6306132 | Moorman et al. | Oct 2001 | B1 |
6325796 | Berube et al. | Dec 2001 | B1 |
6330479 | Stauffer | Dec 2001 | B1 |
6346104 | Daly et al. | Feb 2002 | B2 |
6347251 | Deng | Feb 2002 | B1 |
6350262 | Ashley | Feb 2002 | B1 |
6355033 | Moorman et al. | Mar 2002 | B1 |
6383182 | Berube et al. | May 2002 | B1 |
6405733 | Fogarty et al. | Jun 2002 | B1 |
6471696 | Berube et al. | Oct 2002 | B1 |
6496737 | Rudie et al. | Dec 2002 | B2 |
6496738 | Carr | Dec 2002 | B2 |
6506189 | Rittman, III et al. | Jan 2003 | B1 |
6512956 | Arndt et al. | Jan 2003 | B2 |
6514251 | Ni et al. | Feb 2003 | B1 |
6530922 | Cosman et al. | Mar 2003 | B2 |
6564806 | Fogarty et al. | May 2003 | B1 |
6569159 | Edwards et al. | May 2003 | B1 |
6589234 | Lalonde et al. | Jul 2003 | B2 |
6592579 | Arndt et al. | Jul 2003 | B2 |
6663624 | Edwards et al. | Dec 2003 | B2 |
6675050 | Arndt et al. | Jan 2004 | B2 |
6685700 | Behl et al. | Feb 2004 | B2 |
6699241 | Rappaport et al. | Mar 2004 | B2 |
6706040 | Mahon et al. | Mar 2004 | B2 |
6722371 | Fogarty et al. | Apr 2004 | B1 |
6752154 | Fogarty et al. | Jun 2004 | B2 |
6752767 | Turovskiy et al. | Jun 2004 | B2 |
6823218 | Berube | Nov 2004 | B2 |
6852091 | Edwards et al. | Feb 2005 | B2 |
6878147 | Prakash et al. | Apr 2005 | B2 |
7070595 | Ormsby et al. | Jul 2006 | B2 |
7128739 | Prakash et al. | Oct 2006 | B2 |
7147632 | Prakash et al. | Dec 2006 | B2 |
7174217 | Rioux et al. | Feb 2007 | B2 |
7190989 | Swanson et al. | Mar 2007 | B1 |
7207985 | Duong et al. | Apr 2007 | B2 |
7217282 | Ginsburg et al. | May 2007 | B2 |
7229437 | Johnson et al. | Jun 2007 | B2 |
7231259 | Jenney et al. | Jun 2007 | B2 |
7234225 | Johnson et al. | Jun 2007 | B2 |
7234977 | Westlund et al. | Jun 2007 | B2 |
7235070 | Vanney | Jun 2007 | B2 |
7238166 | Callister | Jul 2007 | B2 |
7238184 | Megerman et al. | Jul 2007 | B2 |
7238194 | Monstadt et al. | Jul 2007 | B2 |
7241293 | Davison | Jul 2007 | B2 |
7244254 | Brace et al. | Jul 2007 | B2 |
7245955 | Rashidi | Jul 2007 | B2 |
7264619 | Venturelli | Sep 2007 | B2 |
7270656 | Gowda et al. | Sep 2007 | B2 |
7270658 | Woloszko et al. | Sep 2007 | B2 |
7270659 | Ricart et al. | Sep 2007 | B2 |
7270661 | Dahla et al. | Sep 2007 | B2 |
7270662 | Visram et al. | Sep 2007 | B2 |
7271363 | Lee et al. | Sep 2007 | B2 |
7273480 | Young et al. | Sep 2007 | B2 |
7276061 | Schaer et al. | Oct 2007 | B2 |
7282049 | Orszulak et al. | Oct 2007 | B2 |
7285116 | de la Rama et al. | Oct 2007 | B2 |
7293562 | Malecki et al. | Nov 2007 | B2 |
7300438 | Falwell et al. | Nov 2007 | B2 |
7301131 | Gauthier et al. | Nov 2007 | B2 |
7306592 | Morgan et al. | Dec 2007 | B2 |
7309325 | Mulier et al. | Dec 2007 | B2 |
7309336 | Ashley et al. | Dec 2007 | B2 |
7311702 | Tallarida et al. | Dec 2007 | B2 |
7311703 | Turovskiy et al. | Dec 2007 | B2 |
7311705 | Sra | Dec 2007 | B2 |
7317949 | Morrison et al. | Jan 2008 | B2 |
7318822 | Darmos et al. | Jan 2008 | B2 |
7318823 | Sharps et al. | Jan 2008 | B2 |
7318824 | Prakash et al. | Jan 2008 | B2 |
7319904 | Cross, Jr. et al. | Jan 2008 | B2 |
7326204 | Paul et al. | Feb 2008 | B2 |
7326205 | Paul et al. | Feb 2008 | B2 |
7326206 | Paul et al. | Feb 2008 | B2 |
7331957 | Woloszko et al. | Feb 2008 | B2 |
7337009 | Schell | Feb 2008 | B2 |
9023024 | Rick | May 2015 | B2 |
20010001819 | Lee et al. | May 2001 | A1 |
20010008966 | Arndt et al. | Jul 2001 | A1 |
20010020178 | Arndt et al. | Sep 2001 | A1 |
20010020180 | Arndt et al. | Sep 2001 | A1 |
20010037812 | Dobak et al. | Nov 2001 | A1 |
20020022832 | Mikus et al. | Feb 2002 | A1 |
20020087151 | Mody et al. | Jul 2002 | A1 |
20020133148 | Daniel et al. | Sep 2002 | A1 |
20020147444 | Shah et al. | Oct 2002 | A1 |
20020198520 | Coen et al. | Dec 2002 | A1 |
20030004506 | Messing | Jan 2003 | A1 |
20030065317 | Rudie et al. | Apr 2003 | A1 |
20030069578 | Hall et al. | Apr 2003 | A1 |
20030078573 | Truckai et al. | Apr 2003 | A1 |
20030088242 | Prakash et al. | May 2003 | A1 |
20030109862 | Prakash et al. | Jun 2003 | A1 |
20030195499 | Prakash et al. | Oct 2003 | A1 |
20040078038 | Desinger et al. | Apr 2004 | A1 |
20040167517 | Desinger et al. | Aug 2004 | A1 |
20040168692 | Fogarty et al. | Sep 2004 | A1 |
20040243200 | Turner et al. | Dec 2004 | A1 |
20040267156 | Turovskiy et al. | Dec 2004 | A1 |
20050015081 | Turovskiy et al. | Jan 2005 | A1 |
20050065508 | Johnson et al. | Mar 2005 | A1 |
20050085881 | Prakash et al. | Apr 2005 | A1 |
20050107783 | Tom et al. | May 2005 | A1 |
20050148836 | Kleen et al. | Jul 2005 | A1 |
20050159741 | Paul et al. | Jul 2005 | A1 |
20060259024 | Turovskiy et al. | Nov 2006 | A1 |
20060264923 | Prakash et al. | Nov 2006 | A1 |
20060282069 | Prakash et al. | Dec 2006 | A1 |
20060287649 | Ormsby et al. | Dec 2006 | A1 |
20070027451 | Desinger et al. | Feb 2007 | A1 |
20070073282 | McGaffigan et al. | Mar 2007 | A1 |
20070123765 | Hetke et al. | May 2007 | A1 |
20070129715 | Eggers et al. | Jun 2007 | A1 |
20070135879 | McIntyre et al. | Jun 2007 | A1 |
20070142829 | Ahn et al. | Jun 2007 | A1 |
20070149964 | Kawabata et al. | Jun 2007 | A1 |
20070156048 | Panescu et al. | Jul 2007 | A1 |
20070156128 | Jimenez | Jul 2007 | A1 |
20070156132 | Drysen | Jul 2007 | A1 |
20070156133 | McDaniel et al. | Jul 2007 | A1 |
20070173680 | Rioux et al. | Jul 2007 | A1 |
20070173798 | Adams et al. | Jul 2007 | A1 |
20070173812 | Bonan et al. | Jul 2007 | A1 |
20070179375 | Fuimaono et al. | Aug 2007 | A1 |
20070179497 | Eggers et al. | Aug 2007 | A1 |
20070185478 | Cosentino | Aug 2007 | A1 |
20070191825 | Cronin et al. | Aug 2007 | A1 |
20070203551 | Cronin et al. | Aug 2007 | A1 |
20070208334 | Woloszko et al. | Sep 2007 | A1 |
20070208335 | Woloszko et al. | Sep 2007 | A1 |
20070208383 | Williams | Sep 2007 | A1 |
20070213700 | Davison et al. | Sep 2007 | A1 |
20070213703 | Naam et al. | Sep 2007 | A1 |
20070215163 | Harrington et al. | Sep 2007 | A1 |
20070219551 | Honour et al. | Sep 2007 | A1 |
20070225701 | O'Sullivan | Sep 2007 | A1 |
20070233057 | Konishi | Oct 2007 | A1 |
20070244529 | Choi et al. | Oct 2007 | A1 |
20070250053 | Fernald et al. | Oct 2007 | A1 |
20070250054 | Drake | Oct 2007 | A1 |
20070250055 | Johnson et al. | Oct 2007 | A1 |
20070250056 | Vanney | Oct 2007 | A1 |
20070255276 | Sliwa et al. | Nov 2007 | A1 |
20070260235 | Podhajsky | Nov 2007 | A1 |
20070260237 | Sutton et al. | Nov 2007 | A1 |
20070270679 | Nguyen et al. | Nov 2007 | A1 |
20070270791 | Wang et al. | Nov 2007 | A1 |
20070276361 | Stevens-Wright et al. | Nov 2007 | A1 |
20070276362 | Rioux et al. | Nov 2007 | A1 |
20070282323 | Woloszko et al. | Dec 2007 | A1 |
20070282324 | Vaska et al. | Dec 2007 | A1 |
20070282325 | Young et al. | Dec 2007 | A1 |
20070287995 | Mayse | Dec 2007 | A1 |
20070287998 | Sharareh et al. | Dec 2007 | A1 |
20070293853 | Truckai et al. | Dec 2007 | A1 |
20070293854 | Pless et al. | Dec 2007 | A1 |
20070293855 | Sliwa et al. | Dec 2007 | A1 |
20070299488 | Carr | Dec 2007 | A1 |
20080004614 | Burdette et al. | Jan 2008 | A1 |
20080004618 | Johnson et al. | Jan 2008 | A1 |
Number | Date | Country |
---|---|---|
0 521 264 | Jan 1993 | EP |
0 667 126 | Aug 1995 | EP |
1 810 627 | Jul 2007 | EP |
200137775 | Feb 2001 | JP |
9320767 | Oct 1993 | WO |
9320768 | Oct 1993 | WO |
9634571 | Nov 1996 | WO |
9748449 | Dec 1997 | WO |
9748450 | Dec 1997 | WO |
9748451 | Dec 1997 | WO |
9956642 | Nov 1999 | WO |
9956643 | Nov 1999 | WO |
9956812 | Nov 1999 | WO |
0049957 | Aug 2000 | WO |
0051513 | Sep 2000 | WO |
0057811 | Oct 2000 | WO |
0160235 | Aug 2001 | WO |
02078777 | Oct 2002 | WO |
03034932 | May 2003 | WO |
03039385 | May 2003 | WO |
03047043 | Jun 2003 | WO |
03088806 | Oct 2003 | WO |
03088858 | Oct 2003 | WO |
2005011049 | Feb 2005 | WO |
2005016119 | Feb 2005 | WO |
Entry |
---|
US 5,326,343, 7/1994, Rudie et al. (withdrawn). |
I Chou, C.K., “Radiofrequency Hyperthermia in Cancer Therapy,” Biologic Effects of Nonionizing Electromagnetic Fields, Chapter 94, CRC Press, Inc., (1995), pp. 1424-1428. |
International Search Report—EP 06 00 9435 dated Jul. 13, 2006. |
Japanese Official Action and Preliminary Report from Appl. No. JP 2008-161057 dated Dec. 14, 2012. |
Canadian Office Action from Appl. No. 2,635,389 dated Feb. 17, 2017. |
Number | Date | Country | |
---|---|---|---|
20150223886 A1 | Aug 2015 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11820679 | Jun 2007 | US |
Child | 14691080 | US |